- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02115165
A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell Tumors (CABA-GCT)
A Prospective Phase II Trial of Cabazitaxel in Male Patients With Chemotherapy Pre-treated Metastatic Nonseminomatous Germ-cell Tumors
Cabazitaxel is a new generation taxane with a high capacity for blood-brain barrier crossing and limited peripheral neuro-toxicity, two major potential advantages in patients with advanced NSGCTs.
Cabazitaxel has a broader in vitro spectrum of activity than docetaxel. Taxanes have demonstrated activity in pre-treated GCTs and are now part of standard treatment, but cabazitaxel has not yet been tested in patients with NSGCT.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Karim FIZAZI, MD-PhD
- Phone Number: +33 0142116264
- Email: karim.fizazi@gustaveroussy.fr
Study Contact Backup
- Name: Géraldine MARTINEAU, MD
- Phone Number: +33 0142115607
- Email: geraldine.martineau@gustaveroussy.fr
Study Locations
-
-
Val de Marne
-
Villejuif, Val de Marne, France, 94805
- Recruiting
- Gustave Roussy Cancer Campus Grand Paris
-
Contact:
- Karim FIZAZI, MD-PhD
- Phone Number: +33 0142116264
- Email: karim.fizazi@gustaveroussy.fr
-
Contact:
- Géraldine MARTINEAU, MD
- Phone Number: +33 01422115607
- Email: geraldine.martineau@gustaveroussy.fr
-
Principal Investigator:
- Karim FIZAZI, MD-PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male patients aged 15 years or older
- Evidence of advanced NSGCT documented either by pathology or by elevated tumor markers (AFP or hCG) and a compatible clinical presentation
- Primary site located in either the testis, the retroperitoneum or the mediastinum
- Progressive disease after at least 2 lines of chemotherapy for advanced NSGCT (ie, non-stage I)
- In case of brain metastases, confirm that patients should be stable / controlled with corticosteroid/anti seizures agents
- No other progressive carcinoma within previous the 5 years, except for basal-cell carcinoma of the skin
- Life expectancy >/= 3 months
- Adequate hematologic function :
- Hemoglobin >/= 10.0 g/dL
- Absolute neutrophil count >/= 1.5 x 10 ^ 9/L,
- Platelet count >/= 100 x 10 ^ 9/L,
- Adequate organ function
- Serum creatinine < 1.5 x ULN. If serum creatinine 1.0 - 1.5 x ULN, creatinine clearance calculated (or measured) according to CKD-EPI formula (see Appendix B) > 60 mL/min
- AST/SGOT and ALT/SGPT </= 1.5 x ULN
- Bilirubin </= 1.5 x ULN
- Information delivered to patient and informed consent form signed by the patient or his legal representative
- Patient affiliated to a social security system or beneficiary of the same
Exclusion Criteria:
- Patients receiving anti cancer therapy within 4 weeks prior to enrolment
- Previous radiotherapy within 4 weeks prior to enrolment
- Serious uncontrolled concurrent medical illness
- History of severe hypersensitivity reaction (>/= grade 3) to polysorbate 80 containing drugs or to other taxanes
- Concurrent or planned treatment with strong inhibitors or strong inducers of cytochrome P450 3A4/5 (see Appendix A). A one week wash-out period is necessary for patients who are already on these treatments.
- Patient with reproductive potential not implementing accepted and effective method of contraception for up to 6 months after the last dose of cabazitaxel.
- Active Grade >/= 3 peripheral neuropathy
- Patients who have had a major surgery within 4 last weeks prior enrolment
- Uncontrolled cardiac arrhythmias, angina pectoris, and/or hypertension. History of congestive heart failure (NYHA III or IV) or myocardial infarction within last 6 months is also not allowed
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cabazitaxel
|
On Day 1 of each cycle, patients will receive cabazitaxel at a dose of 25 mg/m², administered by IV route in 1 hour
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Favorable response
Time Frame: Assessed every 6 weeks from start of treatment up to 72 months
|
To evaluate the favorable response rate of cabazitaxel treatment in patients with highly-pretreated nonseminomatous germ-cell tumors (NSGCT)
|
Assessed every 6 weeks from start of treatment up to 72 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response rate on brain metastases
Time Frame: Assessed every 6 weeks after treatment start up to 72 months
|
MRI of the brain every 6 weeks only in case of brain metastases detected at baseline and for all patients at the end of the study. Evaluation will be made using RECIST V1.1 |
Assessed every 6 weeks after treatment start up to 72 months
|
Progression free survival
Time Frame: Assessed every 6 weeks from treatment start to progression up to 72 months
|
Assessed every 6 weeks from treatment start to progression up to 72 months
|
|
Overall survival
Time Frame: Assessed every 3 weeks after treatment start up to 72 months
|
Assessed every 3 weeks after treatment start up to 72 months
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Karim FIZAZI, MD-PhD, Gustave Roussy, Cancer Campus, Grand Paris
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013-000286-36
- 2012/1950 (Other Identifier: CSET number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-seminomatous Germ-cell Tumors
-
Centre Francois BaclesseCompletedMetastasis | Non-seminomatous Germ Cell TumorsFrance
-
Gustave Roussy, Cancer Campus, Grand ParisRecruitingNon-Seminomatous Germ Cell TumorFrance
-
Nabil AdraRecruitingOvarian Germ Cell Tumor | Germ Cell Tumor | Non-seminomatous Germ Cell TumorUnited States
-
Jennifer KingExelixisRecruitingOvarian Germ Cell Tumor | Seminoma | Germ Cell Tumor | Non-seminomatous Germ Cell TumorUnited States
-
Heinrich-Heine University, DuesseldorfUnknownStage II A/B Seminomatous Germ Cell TumorsGermany
-
Institute of Cancer Research, United KingdomCancer Research UK; University Hospital Birmingham NHS Foundation TrustUnknownStage I Testicular Non-Seminomatous Germ Cell TumorUnited Kingdom
-
Nasser Hanna, M.D.Merck Sharp & Dohme LLC; Hoosier Cancer Research NetworkTerminatedGenital Neoplasms, Female | Testicular Neoplasms | Genital Neoplasms, Male | Ovarian Neoplasms | Mediastinal Neoplasms | Germ Cell Neoplasms | Non Seminomatous Germ Cell TumorsUnited States
-
Indiana University School of MedicineAlaunos TherapeuticsTerminatedStage IV Ovarian Germ Cell Tumor | Recurrent Ovarian Germ Cell Tumor | Extragonadal Seminoma | Recurrent Malignant Testicular Germ Cell Tumor | Stage IV Extragonadal Non-Seminomatous Germ Cell Tumor | Stage IV Extragonadal Seminoma | Adult Central Nervous System Germ Cell Tumor | Adult Teratoma | Malignant... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedStage IV Ovarian Germ Cell Tumor | Recurrent Ovarian Germ Cell Tumor | Stage III Testicular Cancer | Recurrent Malignant Testicular Germ Cell Tumor | Recurrent Extragonadal Seminoma | Recurrent Malignant Extragonadal Germ Cell Tumor | Recurrent Malignant Extragonadal Non-Seminomatous Germ Cell... and other conditionsUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI); Cancer Research UK; European Organisation for... and other collaboratorsActive, not recruitingSeminoma | Teratoma | Choriocarcinoma | Germinoma | Germ Cell Tumor | Yolk Sac Tumor | Mixed Germ Cell Tumor | Childhood Teratoma | Malignant Germ Cell Neoplasm | Extragonadal Seminoma | Non-seminomatous Germ Cell TumorUnited States, Germany, France, Spain, Netherlands, Australia, Belgium, Switzerland, United Kingdom, Italy, Denmark, Ireland
Clinical Trials on Cabazitaxel
-
Jeffrey Yachnin M.D., PhD.SanofiCompletedMetastatic Castration Resistant Prostate CancerSweden
-
Krzysztof MisiukiewiczSanofi; Icahn School of Medicine at Mount SinaiCompleted
-
Vejle HospitalSanofiTerminated
-
Azienda Socio Sanitaria Territoriale degli Spedali...San Luigi Gonzaga HospitalUnknown
-
Institut für Klinische Krebsforschung IKF GmbH...Completed
-
Rambam Health Care CampusCompleted
-
University Hospitals Bristol and Weston NHS Foundation...SanofiCompletedPenile NeoplasmUnited Kingdom
-
Brown UniversityTerminated
-
European Organisation for Research and Treatment...SanofiCompletedDedifferentiated LiposarcomaUnited Kingdom, Belgium, France, Italy
-
Vejle HospitalCompleted